1. Immunohistochemical Surrogates for Molecular Pathology
   Ayca Ersen Danyeli, 2021, Precision Molecular Pathology of Glioblastoma CrossRef
2. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
   Kenta Suzuki et al, 2021, EJNMMI Research CrossRef
3. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics
   Artemiy Silantyev et al, 2019, Cells CrossRef
4. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome
   Thomas R. Reich et al, 2017, Oncotarget CrossRef
5. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update
   Jeffrey D. Goldsmith et al, 2024, Archives of Pathology & Laboratory Medicine CrossRef
6. Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models
   Ming Yuan et al, 2021, Neuro-Oncology CrossRef
7. The Clinical Utility of a Tiered Approach to Pediatric Glioma Molecular Characterization for Resource-Limited Settings
   Rawan Hammad et al, 2024, JCO Global Oncology CrossRef
8. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria
   Michela Visani et al, 2017, Journal of Neuro-Oncology CrossRef
9. Detección de la mutación de la enzima isocitrato deshidrogenasa en gliomas difusos grados II, III y IV
   Pablo Naranjo-Botero et al, 2021, Medicina y Laboratorio CrossRef